Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BOTANIX PHARMACEUTICALS LTD Director's Dealing 2022

Mar 21, 2022

64551_rns_2022-03-21_2a5d8c3d-ee98-42bd-907b-3864e2bae123.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Botanix Pharmaceuticals Limited ACN 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Daniel Sharp
Date of last notice 22/03/2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest. DJMB Corporate Pty Ltd(Mr Sharp is a director of DJMB Corporate Pty Ltd)
Date of change 22/03/2022
No. of securities held prior to change Nil
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class Unlisted options
Number acquired 5,000,000
Number disposed -
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation Nil
No. of securities held after changeDJMB Corporate Pty Ltd 1,000,000 Unlisted Options exercisable at0.071 each, expiring 22 March 20224,000,000 Unlisted Options exercisable at0.094 each, expiring 22 March 2025 andvesting progressively over three years.
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participationin buy-back Issue of Options under the Company’sEmployeeSecuritiesIncentivePlantoprovide incentive for future performance

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder(if issued securities) N/A
Date of change N/A
  • See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest N/A
related prior to change
Note: Details are only required for a contract in relation to which the interest
has changed
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Note: If consideration is non-cash, provide details and an estimated
valuation
Interest after change N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts No
detailed above traded during a +closed period where
prior written clearance was required?
If so, was prior written clearance provided to allow N/A
the trade to proceed during this period?
If prior written clearance was provided, on what date N/A
was this provided?
  • See chapter 19 for defined terms.

Appendix 3Y Page 3